e-learning
resources
Munich 2014
Tuesday, 09.09.2014
Thoracic tumours: news from the lab
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
MMP-9 responsive mesoporous silica nanoparticles for local drug delivery to NSCLC cells
D. A. Bölükbas, C. Argyo, O. Eickelberg, T. Bein, S. Meiners, S. H. Van Rijt (Munich, Germany)
Source:
International Congress 2014 – Thoracic tumours: news from the lab
Session:
Thoracic tumours: news from the lab
Session type:
Oral Presentation
Number:
3289
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. A. Bölükbas, C. Argyo, O. Eickelberg, T. Bein, S. Meiners, S. H. Van Rijt (Munich, Germany). MMP-9 responsive mesoporous silica nanoparticles for local drug delivery to NSCLC cells. Eur Respir J 2014; 44: Suppl. 58, 3289
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Combinatorial delivery of targeted mesoporous silica nanoparticles for lung cancer therapy
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Mesoporous silica-based nanoparticles for targeted delivery of proteasome inhibitors to the lung
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013
Encapsulation of vinorelbine in polymeric nanoparticles improves efficacy in cancer cells and reduces inflammation in non-cancer cells
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
The research on early detection of lung cancer with exhaled volatile organic compounds
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Functional impairment of NK cells in non-small-cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Metabolic modification as a potential therapeutics approach in lung cancer
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Polymorphism of
HLA-G
gene promotor in patients with non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Antitumor efficacy of the double suicide genesin lung cancer cells
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Metabolomic analysis of serum samples from patients with lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept